CJC-1295 vs Hexarelin
Side-by-Side Comparison
| Attribute | Cjc 1295 | Hexarelin |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | Hexarelin binds to and activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus through a triple mechanism: direct stimulation of pituitary somatotroph... |
| Evidence Rating | D — Preclinical | C — Phase I–II Clinical Trials |
| Clinical Status | Research-only / Not approved for human use | Phase II completed. Development discontinued due to tolerance/desensitization concerns. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Generally well-tolerated in clinical trials; Transient cortisol and prolactin elevation at higher doses |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 100-300 mcg/injection; most protocols use 200 mcg 2x daily |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | 1-3 times daily (commonly twice daily) |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~887 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~70 minutes |
Overview
CJC-1295 and Hexarelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Hexarelin — Mechanism & Evidence
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a). It is considered one of the most potent GHRPs available, stimulating greater GH release than GHRH alone. However, it causes relatively rapid receptor desensitization compared to milder GHRPs like ipamorelin, limiting cycle duration to 4-8 weeks. It also has notable cardioprotective properties independent of GH release.
Key claims: Potent GH release; Cardioprotective effects; Improves body composition.
Shared Research Applications
Both peptides are studied for: Anti-Aging, Body Composition.
CJC-1295 is also researched for: no additional unique applications.
Hexarelin is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Hexarelin: Generally well-tolerated in clinical trials Transient cortisol and prolactin elevation at higher doses Hunger increase (ghrelin receptor activation)
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Hexarelin: Potent GH Secretagogue Mechanisms and Research
Hexarelin, a synthetic hexapeptide developed in Italy in the early 1990s, stands out for its strong growth hormone pulse amplification among GHRP compounds. Research highlights its action on GHS-R1a receptors and unique cardioprotective effects via CD36 binding, independent of GH release. Studies like Ghigo et al. (1994) and Muccioli et al. (2001) document its potency and distinct pathways, making it valuable for GH axis and cardiac research.